Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 7,968 shares at $25.70 ($203K) on 2021-08-26, disclosed to the SEC on 2021-08-30.
Open-market sale of $203k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.70 | 1,532 | $38K | 18.6% |
| 2 | $25.70 | 3,218 | $83K | 40.7% |
| 3 | $25.70 | 3,218 | $83K | 40.7% |
| Total | $25.51 avg | 7,968 | $203K | 100% |
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |